fda warning about compounded semaglutide The growing availability of GLP-1 weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. https://www.abc27.com/national/compounded -glp-1-drugs-creating-concern-among-doctors-and-fda/?utm_medium Semaglutide Safety Alerts, Recalls &

The share who report ever taking these drugs rises to four in ten (43%) among adults who have been told by a doctor that they have diabetes, a quarter who have been told they have heart disease, and one in five (22%) who have been told by a doctor that they are overweight or obese in the past five years 1

Others may need targeted probiotics or longer-term dietary consistency to see the same effects

Lipid Panel: Clinical studies have demonstrated that semaglutide may modestly improve lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides

Obesity has a large number of short- and long-term complications, as well as a potential economic impact [10]